Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer manipulated Neurontin studies, experts allege in fraud case

This article was originally published in Scrip

Executive Summary

Plaintiffs seeking class-action status in US multi-district litigation against Pfizerhave submitted newly filed documents allegedly showing that some of the company's top marketers tried to alter the conclusions of studies or suppress negative information from studies that found no beneficial effect from Neurontin (gabapentin) for various off-label conditions. The case relates to a broad effort by Neurontin users and third-party payers to sue the company for alleged consumer fraud.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts